Donnerstag, 24. Oktober 2019
Navigation öffnen
Anzeige:

JOURNAL ONKOLOGIE – STUDIE

STRONG An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

Rekrutierend

NCT-Nummer:
NCT03084471

Studienbeginn:
April 2017

Letztes Update:
22.10.2019

Wirkstoff:
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab

Indikation (Clinical Trials):
Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
AstraZeneca

Collaborator:
-

Kontakt

AstraZeneca Clinical Study Information Center
Kontakt:
Phone: 1-877-240-9479
E-Mail: information.center@astrazeneca.com
» Kontaktdaten anzeigen

Studienlocations (3 von 160)

Research Site
33611 Bielefeld
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Research Site
47179 Duisburg
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Research Site
40225 Düsseldorf
(Nordrhein-Westfalen)
GermanyZurückgezogen» Google-Maps
Research Site
45136 Essen
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Research Site
33332 Guetersloh
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Research Site
24116 Kiel
(Schleswig-Holstein)
GermanyRekrutierend» Google-Maps
Research Site
23538 Lübeck
(Schleswig-Holstein)
GermanyRekrutierend» Google-Maps
Research Site
48149 Muenster
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Research Site
48149 Münster
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Research Site
18057 Rostock
(Mecklenburg-Vorpommern)
GermanyRekrutierend» Google-Maps
Research Site
70174 Stuttgart
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Research Site
72076 Tübingen
(Baden-Württemberg)
GermanyZurückgezogen» Google-Maps
Research Site
99508 Anchorage
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
92130-3318 San Diego
United StatesZurückgezogen» Google-Maps
Research Site
33401 West Palm Beach
United StatesZurückgezogen» Google-Maps
Research Site
60487 Tinley Park
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
27157 Winston-Salem
United StatesNoch nicht rekrutierend» Google-Maps
Research Site
8934 AD Leeuwarden
NetherlandsNoch nicht rekrutierend» Google-Maps
Research Site
SW3 6JJ London
United KingdomNoch nicht rekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Detailed Description:

This is an open-label, multi-center, study to determine the short and long term safety of fixed doses of durvalumab 1500 mg + tremelimumab 75 mg combination therapy or durvalumab 1500 mg monotherapy in patients with advanced solid malignancies. This study is modular in design, one or more of the modules will be opened in a given country / region based on local patient population prevalence, and results of feasibility studies. The total number of patients to be enrolled overall and in each module will depend on the types and number of tumor modules added to the main study and country-specific ancillary studies. The number of patients and sites to be involved in individual countries will be dependent on each module or ancillary study. This study consisted of a screening period, a treatment period, a 90 day safety follow-up period and a survival follow-up period. Patients will receive the investigation product (IP) via intravenous (IV) infusion once every 4 weeks (Q4W) in combination therapy or monotherapy as mentioned below - Combination therapy: Durvalumab 1,500 mg + tremelimumab 75 mg on Week 0, for up to a maximum of 4 doses (or cycles) followed by durvalumab 1,500 mg starting 4 weeks after the last infusion of the combination or discontinuation of tremelimumab.

Monotherapy: Durvalumab 1,500 mg on week 0.

Patients will attend a safety follow-up visit 90 days after study treatment discontinuation. Thereafter, patients will be contacted by phone or electronic communication every 3 months for survival status up to 5 years following date of first patient treatment initiation. All patients will be followed for a minimum of 6 months following enrolment of last patient. It is anticipated that the total enrolment period for the overall study will be approximately 2 to 3 years, with an overall duration of approximately 5 years.

Ein-/Ausschlusskriterien

Inclusion Criteria:

1. Must have a life expectancy of at least 12 weeks.

2. Age ≥ 18 years at the time of screening. For patients aged <20 years and enrolled in Japan, a written informed consent should be obtained from the patient and his or her legally acceptable representative

3. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act in the US, European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.

4. Disease not amendable to curative surgery

5. Eastern Cooperative Oncology Group (ECOG) performance status as defined in the specific module.

6. Body weight >30 kg.

7. No prior exposure to anti-programmed death (PD) 1 or anti-PD-ligand (L) 1.

8. Adequate organ and marrow function.

9. Female patients of childbearing potential (i.e., not surgically sterile or post-menopausal) who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from the time of screening and must agree to continue using such precautions for 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy.

10. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

- Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).

- Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

11. Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 180 days after receipt of the final dose of durvalumab + tremelimumab combination therapy or 90 days after receipt of the final dose of durvalumab monotherapy.

For inclusion in the Module A of the study patients should fulfill the following criteria:

1. Histologically or cytologicaly confirmed locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract (including the urinary bladder, ureter, urethra and renal pelvis)

2. Disease that has progressed during or after at least one previous platinum or nonplatinum based chemotherapy, either for metastatic disease or progressive disease less than 12 months after adjuvant or neo-adjuvant chemotherapy

3. ECOG performance status 0-2

Exclusion Criteria:

1. Involvement in the planning and/or conduct of the study.

2. Previous IP assignment in the present study.

3. Concurrent enrollment in another clinical study or another sub-study of this protocol, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.

4. Participation in another clinical study with an IP and receipt of any investigational anticancer therapy during the last / within 28 days or 5 half-lives, whichever is shorter, prior to the first dose of study treatment.

5. Any concurrent chemotherapy, investigational agent, biologic, or hormonal therapy for cancer treatment.

6. Local treatment of isolated lesions for palliative intent is acceptable (e.g., local surgery or radiotherapy).

7. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.

8. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.

9. History of allogenic organ transplantation.

10. Uncontrolled intercurrent illness (ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.

11. History of another primary malignancy, leptomeningeal carcinomatosis and active primary immunodeficiency.

12. Has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis identified either on baseline brain imaging (please refer to RECIST for details on the imaging modality) obtained during the screening period or identified prior to signing the ICF. Brain metastases will not be recorded as RECIST Target Lesions at baseline.

13. Active infection including tuberculosis, hepatitis B virus, hepatitis C virus, or human immunodeficiency virus (positive HIV ½ antibodies).

14. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab.

15. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]).

16) Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.

17) Known allergy or hypersensitivity to study drug(s) or compounds of similar biologic composition to the study drug(s), or any of the study drug excipients.

18) Any unresolved NCI CTCAE Grade ≥2 toxicities from prior anti-cancer therapy with the exception of vitiligo, alopecia, and the laboratory values defined in the inclusion criteria.

19) Pregnant or breastfeeding women or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy.

20) Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.

Studien-Rationale

Primary outcome:

1. Safety: Number of patients with adverse events of special interest (AESIs). (Time Frame - From screening to safety follow up visit (90 days after last dose).):
To assess the AESIs as a criteria of safety and tolerability variables.



Secondary outcome:

1. Safety: Number of patients with treatment-emergent adverse events (TEAEs). (Time Frame - From screening to safety follow up visit (90 days after last dose).):
To assess the incidence, severity, nature, seriousness, intervention/treatment, outcome, and causality of TEAEs (including serious adverse events [SAEs])

2. Safety: Number of patients who discontinued treatment due to TEAEs (including SAEs). (Time Frame - From screening to safety follow up visit (90 days after last dose).):
To assess the incidence and frequency of durvalumab ± tremelimumab discontinuation due to TEAEs (including SAEs)

3. Safety: Number of patients who had treatment interrupted due to TEAEs (including SAEs). (Time Frame - From screening to safety follow up visit (90 days after last dose).):
To assess the incidence and frequency of durvalumab ± tremelimumab interruption due to TEAEs (including SAEs).

4. Efficacy: Overall survival (OS) rate (Time Frame - Up to 5 years following date of first patient treatment initiation.):
Overall survival was defined as the time from the first date of treatment until death due to any cause. To assess OS of durvalumab + tremelimumab combination therapy or durvalumab monotherapy.

Studien-Arme

  • Experimental: Combination therapy
    Combination therapy (durvalumab + tremelimumab) : Patients will receive the combination therapy followed by monotherapy via intravenous (IV) infusion once Q4W: Durvalumab 1,500 mg + tremelimumab 75 mg on Week 0, for up to a maximum of 4 doses (or cycles) and Durvalumab 1,500 mg starting 4 weeks after the last infusion of the combination or discontinuation of tremelimumab.
  • Experimental: Monotherapy
    Monotherapy (Durvalumab 1,500 mg): Patients will receive durvalumab 1,500 mg via IV infusion Q4W on Week 0.

Geprüfte Regime

  • MEDI4736 (Durvalumab):
    A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).
  • MEDI4736 (Durvalumab) + Tremelimumab:
    Durvalumab: A human mAb of IgG 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on IC. Tremelimumab: A human Ig G2 mAb that completely blocks the interaction of human CTLA-4 (cluster of differentiation [CD]152) with CD80 and CD86 and increase release of cytokines (interleukin [IL]-2 and interferon [IFN]-γ) from human T cells, peripheral blood mononuclear cells and whole blood.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

11. Krebsaktionstag: Austausch zu Alltagsfragen

11. Krebsaktionstag: Austausch zu Alltagsfragen
Universitätsklinikum Ulm

Senkt Sport das Rückfallrisiko bei Krebs? Welcher Badeanzug steht mir nach der Brustamputation? Wie ernähre ich mich so, dass ich fit bleibe? Um diese und weitere Fragen dreht sich der 11. Krebsaktionstag der Medizinisch-Onkologischen Tagesklinik (MOT) der Klinik für Innere Medizin III des Universitätsklinikums Ulm. Krebspatient*innen, Angehörige und Interessierte sind am Freitag, den 14.09.2018 herzlich eingeladen, sich von 10.00 bis 16.30 Uhr bei kostenfreien Vorträgen...

Individualisierte Schmerztherapie

Individualisierte Schmerztherapie
© Dan Race / Fotolia.com

Schmerz ist eine komplexe Empfindung. Der menschliche Körper besitzt ein weitverzweigtes Netzwerk aus Schmerzrezeptoren und Schmerzleitungen.  Schmerzen können bei Krebserkrankungen durch das Wachstum eines Tumors oder auch durch unerwünschte Begleiterscheinungen von Therapien verursacht werden.  Um das Schmerzerleben adäquat behandeln zu können, ist es notwendig, eine individuelle Schmerztherapie durchzuführen. Die Mitarbeit der Betroffenen ist dabei...

70 Prozent der Deutschen fürchten Tumor, Engagement für Gesundheit wächst

70 Prozent der Deutschen fürchten Tumor, Engagement für Gesundheit wächst
© pressmaster / Fotolia.com

Sieben von zehn Menschen in Deutschland fürchten sich am meisten vor Krebs. Bei Erwachsenen zwischen 30 und 44 Jahren und Frauen ist die Angst besonders groß. Das zeigt eine aktuelle und repräsentative Studie der DAK-Gesundheit. Ein weiteres zentrales Ergebnis: Das Engagement für die eigene Gesundheit wächst. Immer mehr Menschen gehen zu Vorsorgeuntersuchungen und halten sich mit Sport und gesunder Ernährung fit.

ESMO 2019
  • PD-L1-positives NSCLC: Pembrolizumab-Monotherapie bei Patienten mit und ohne Hirnmetastasen vergleichbar wirksam
  • Tumormutationslast etabliert sich als prädiktiver Marker für das Ansprechen auf Pembrolizumab bei soliden Tumoren
  • Hohes und langanhaltendes Ansprechen auf Pembrolizumab-Monotherapie bei unterschiedlichen MSI-H-Tumoren
  • Checkpoint-Inhibition in der adjuvanten und metastasierten Situation hat für Patienten mit Melanom das Überleben neu definiert
  • Magenkarzinom/Adenokarzinom des ösophagogastralen Übergangs: Patienten mit MSI-high-Tumoren profitieren besonders von Checkpoint-Inhibition
  • Pembrolizumab + Chemotherapie beim Plattenepithelkarzinom-NSCLC: Überlegenes OS, PFS, ORR und PFS2 gegenüber alleiniger Chemotherapie
  • Frühes TNBC: signifikant verbesserte pCR-Rate durch neoadjuvante Therapie mit Pembrolizumab + Chemotherapie
  • HNSCC: Pembrolizumab-Monotherapie und kombiniert mit Platin-basierter Chemotherapie erfolgreich in der Erstlinie
  • PD-L1-positives Magenkarzinom und AEG: Vergleichbare Lebensqualität unter Pembrolizumab-Monotherapie und Chemotherapie
  • Pembrolizumab-Monotherapie beim vorbehandelten mTNBC: Klarer Trend zu verbessertem Überleben mit zunehmender PD-L1-Expression